A new modelling study suggests that US Medicare “Most-Favored-Nation” policies on drug prices would cut Medicare spending on brand-name drugs, but potentially incentivize companies to increase prices or delay new drug launches elsewhere. Efforts to control the cost of government spending on drugs culminated in a Most-Favored-Nation (MFN) policy, a Trump administration initiative which ties … Continue reading US Medicare Pricing Policies Could Drive Global Costs and Hinder Access Worldwide